Probability of resistance and means of sensitive and resistant cells at the end of treatment with monotherapy.

Means of the sensitive cells (), resistant cells (), and total tumor size (), as well as the probability of resistance (), are calculated for a tumor with an initial population of 1.6 ⋅ 106 sensitive cells at the end of nine weeks of treatment. The dosing schedules depicted here include both types of monotherapies (erlotinib alone and evofosfamide alone) from all three optimization classes.